Galena Biopharma, Inc. (NASDAQ: GALE) is developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena’s development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax (nelipepimut-S) currently in an international, phase III clinical trial. The company’s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. For more information, visit the company’s website at www.galenabiopharma.com.